Deliver the A-share market information at the first time, observe the market trend, grasp the rise and fall logic and tap investment opportunities.
100 billion market value "growth Mao" Changchun High And New Technology Industries (Group) Inc(000661) flash crash limit, and the share price hit a 22 month low
In the morning of January 19, "growth grass" Changchun High And New Technology Industries (Group) Inc(000661) collapsed. As of press time, the limit has been closed at 227.60 yuan, and the share price has hit a new low since March 2020. On the news, Changchun High And New Technology Industries (Group) Inc(000661) on January 12, it was announced that Changchun Kinsey Pharmaceutical Co., Ltd., the holding subsidiary of the company, received the notice of approval for supplementary drug application approved and issued by the State Food and drug administration, which approved Kinsey pharmaceutical to increase the approved adaptation of the same variety in China, including: for children's short stature caused by achondroplasia; For growth disorders in girls caused by gonadal hypoplasia (Turner syndrome); Adult short bowel syndrome for nutritional support.
According to the third quarterly report of Changchun High And New Technology Industries (Group) Inc(000661) 2021, the company's main revenue was 8.239 billion yuan, a year-on-year increase of 28.75%; The net profit attributable to the parent company was 3.147 billion yuan, a year-on-year increase of 39.25%; Deduct non net profit of RMB 3.16 billion, a year-on-year increase of 43.07%; In the third quarter of 2021, the company's main revenue in a single quarter was 3.276 billion yuan, a year-on-year increase of 31.97%; The net profit attributable to the parent company in a single quarter was 1.224 billion yuan, a year-on-year increase of 28.78%; The non net profit deducted in a single quarter was 1.238 billion yuan, a year-on-year increase of 31.46%; The debt ratio is 22.9%, the investment income is -26.0994 million yuan, the financial expenses are -65.7984 million yuan, and the gross profit margin is 86.71%.
Dongguan securities research report said that the company is the leader of growth hormone, with large market space and good competition pattern in China. Through the above two investments, the company will accelerate the development in the field of newborns and mental nerves, enhance technical reserves, optimize product structure, enhance core competitiveness and promote the healthy and sustainable development of the company.
the huge amount of money game "demon king" Andon Health Co.Ltd(002432) fell again
On the morning of January 19, the big demon stock Andon Health Co.Ltd(002432) opened at the limit price. As of press time, the limit has been opened. On the news side, Andon Health Co.Ltd(002432) the latest risk warning announcement said that the single month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance. The company believes that it is necessary to give risk warning again.
Andon Health Co.Ltd(002432) mentioned eight risks, including: the risk of uncertainty in the development of epidemic situation in the United States, the risk of uncertainty in market competition, the risk of rationality of valuation model, the risk of reliability of information, the risk of exchange rate fluctuation, logistics and transportation risk, quality risk and contract / order risk.
In terms of finance, in 2020, Andon Health Co.Ltd(002432) achieved annual revenue of 2.008 billion yuan and deducted non net profit of 247 million yuan. In the first three quarters of 2021, the company's revenue was only 790 million yuan, a year-on-year decrease of 50.82%; After deducting non net profit, there was a loss of 24.78 million yuan.
Microsoft's $68.7 billion acquisition of Activision Blizzard detonated the game sector Rastar Group(300043) and rose
Boosted by Microsoft's 68.7 billion acquisition of Activision Blizzard, the online game sector rose strongly. As of press time, Rastar Group(300043) "20cm" limit, Capitalonline Date Service Co.Ltd(300846) , Sichuan Xun You Network Technology Co.Ltd(300467) , Hubei Century Network Technology Inc(300494) , Shenzhen Bingchuan Network Co.Ltd(300533) and other gains were ahead. On the news, on January 18 Beijing time, Microsoft announced that it would acquire Activision Blizzard at a price of $95 per share, with a total value of $68.7 billion in all cash transactions. After the completion of the transaction, Microsoft will become the third largest game company in the world after Tencent and Sony. At the same time, Microsoft will also obtain the franchise rights of many game products, including Warcraft, Diablo, watchman, call of duty, candy crush legend and so on.
Some analysts pointed out that with Activision Blizzard joining the Microsoft camp, relevant Chinese cooperative enterprises may benefit from it. Blizzard, which has many IP, sold at a high price this time, may trigger a revaluation of the value of game companies holding A-share IP.
Shanxi Securities Co.Ltd(002500) pointed out that at present, the global mobile game market is facing a new round of strong growth. The scale of China's mobile game market to the sea continues to improve, mainly benefiting from the low penetration of overseas mobile game market, the change of game habits brought by epidemic online dividends and its own excellent game playing quality.
The agency said that according to the game industry report data, the actual revenue of China's self-developed game overseas market in 2021 was US $18.013 billion, with a year-on-year increase of 16.59%. Although the growth rate decreased compared with the same period in 2020, the overall growth rate of 6% in the Chinese market still showed a higher growth trend, and the countries / regions and categories of sea games were more diverse. In the future, the performance of the overseas game market is expected to continue to inject growth power into China's game industry and Chinese game companies. In terms of target, it is suggested to pay attention to the game leading targets in the development of game overseas business in A-share game companies, including Wuhu 37 Interactive Entertainment Network Technology Group Co.Ltd(002555) , G-Bits Network Technology(Xiamen)Co.Ltd(603444) , Zhejiang Century Huatong Group Co.Ltd(002602) , Perfect World Co.Ltd(002624) , Ourpalm Co.Ltd(300315) , Yoozoo Interactive Co.Ltd(002174) .
large infrastructure sector continues to strengthen institutions: infrastructure investment in 2022 may welcome a "good start"
In the morning of January 19, the large infrastructure sector continued to strengthen. As of press time, most stocks in building materials, construction machinery, steel and other sectors have risen. Among them, the building materials sector showed the strongest performance, Beijing Hanjian Heshan Pipeline Co.Ltd(603616) , Yunnan Bowin Technology Industry Co.Ltd(600883) limit, Gansu Shangfeng Cement Co.Ltd(000672) , Anhui Conch Cement Company Limited(600585) , Beijing New Building Materials Public Limited Company(000786) and other stocks rose ahead.
In terms of news, the national development and Reform Commission said at a regular press conference that it should appropriately carry out infrastructure investment in advance, accelerate the promotion of 102 major engineering projects in the 14th five year plan, implement the local government special bonds issued in the fourth quarter of last year to specific projects as soon as possible according to the requirements of "funds follow the projects", and pay close attention to the issuance of the issued quota, Strive to form more physical workload in the first quarter.
Tianfeng Securities Co.Ltd(601162) said that the demand for steady economic growth in 2022q1 may be stronger than that in the past five years. On the premise of accelerated special debt, pre fiscal and sufficient reserves of major projects, it is expected that the growth rate of infrastructure in 2022q1 is expected to improve significantly month on month, with a year-on-year growth rate of more than 5% in a single quarter.
Guotai Junan Securities Co.Ltd(601211) believes that as of January 9, 15 regions such as Fujian, Shaanxi, Shandong, Jiangsu and Zhejiang have disclosed local bond issuance plans in the first quarter, issuing a total of 700.134 billion yuan of new local bonds and 71.25 billion yuan of refinancing bonds. Subsequently, many places such as Henan and Hubei will also continuously disclose special bond issuance plans. Local government special bonds are an important source of funds for local construction projects and play an important role in expanding effective investment. Combined with the statement of "moderately ahead of infrastructure investment" at the central economic work conference, it is expected that the proportion of special bond funds invested in infrastructure will increase. Infrastructure investment is expected to pick up structurally in 2022 and usher in a "good start".
multiple positive catalysis! Media sector rose sharply, and institutions suggested to pay attention to three main investment lines
On January 19, the media sector strengthened. As of press time, Jishi Media Co.Ltd(601929) 3 connected board, Guizhou Bc&Tv Information Network Co.Ltd(600996) 2 connected board, Tvzone Media Co.Ltd(603721) , Simei Media Co.Ltd(002712) and other limits rose, and Chinese Universe Publishing And Media Group Co.Ltd(600373) , Tangel Culture Co.Ltd(300148) and others followed.
The 14th five year plan for digital economy development issued by the State Council recently points out that it will support the cultivation of new business forms of digital economy, promote the healthy development of platform economy, and guide and support platform enterprises to strengthen the integration and sharing of data, products, content and other resources; Improve the multi value transmission and contribution distribution system, and orderly guide the development of new employment and entrepreneurship platforms such as diversified social networking, short video and knowledge sharing.
Tianfeng Securities Co.Ltd(601162) said that in the short term, as an important film season, the box office concentration effect of the Spring Festival is expected to continue. It is suggested to pay attention to the companies related to the Spring Festival. Although the film market has experienced a cold winter in the past two years, the long-term logic of high-quality film and television content and cinema companies has not changed, and it is expected to improve the head concentration. As a post epidemic sector, if the epidemic situation is effectively controlled, the sector can rebound.
In terms of investment opportunities, Central China Securities Co.Ltd(601375) suggests paying attention to: (1) the film sector. The "local Chinese New Year" mode continued in 2022 is also expected to create better box office results, but repeated outbreaks in some parts of China may have a certain negative impact.
(2) game section. It is suggested to grasp the main investment lines such as sea going strategy, cloud games, VR / AR, game product launch cycle and market performance.
(3) virtual human technology. At present, virtual human technology has been tested in large-scale programs on mainstream media platforms. Although at present, virtual human technology is still mainly used in Pan entertainment fields such as virtual idol, e-commerce live broadcast, short video and news variety shows, in the future, the application scenario of virtual human technology may be further expanded to intelligent office, social networking, finance, education, medical treatment and other fields. As one of the underlying technologies of the meta universe, virtual human technology has relatively large application space.
covid-19 active drug concept Hybio Pharmaceutical Co.Ltd(300199) intraday rose again rose by more than 160% in recent months
Covid-19 drug concept was active again on the 19th. As of press time, Hybio Pharmaceutical Co.Ltd(300199) rose by more than 12%, Jinghua Pharmaceutical Group Co.Ltd(002349) rose by the limit, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) , Zhejiang Jianfeng Group Co.Ltd(600668) , Staidson(Beijing) Biopharmaceuticals Co.Ltd(300204) and so on.
It is worth noting that Hybio Pharmaceutical Co.Ltd(300199) has increased by over 160% since December 20, 2021. The company recently issued a risk warning that the company and New Coronavirus Institute of Microbiology of China Academy of Sciences cooperate to develop New Coronavirus polypeptide nasal spray drug. Further, it is necessary to carry out the live virus test, pre clinical research, clinical research of the virus and its variants. There is a risk that the clinical progress and effectiveness do not meet the expectations in many links such as pharmaceutical research and market promotion; There are covid-19 preventive and therapeutic drugs in different research and development stages in the world. Many covid-19 vaccines have been put on the market in China, and many antibodies and small molecule drugs are also in different research and development stages. There is uncertainty in the market competition pattern after the new drug is put on the market; Affected by the development and control of overseas epidemic situation, the selection of drug use, overseas market promotion and other factors, there is still uncertainty whether the clinical trial application and products can be successfully approved for listing.
For covid-19 drugs, Zhongtai Securities Co.Ltd(600918) pointed out that seeking effective drug treatment has been a priority since the outbreak of covid-19. Compared with macromolecular drugs (such as neutralizing antibody drugs), small molecular oral drugs have the advantages of direct antiviral effect, low production cost and medication cost, easy storage and transportation conditions, convenient administration and good patient compliance. Oral covid-19 drugs are expected to become a more convenient choice for the treatment of covid-19 pneumonia in the future. At present, there are two small molecule drugs approved by EUA in the world, namely, Mercure East muppeville and Pfizer paxlovid; China is not included in the generic drug licensing agreement signed with MPP (drug patent pool). Therefore, domestic covid-19 oral drugs are in a very important strategic position for epidemic prevention and control in China.
Southwest Securities Co.Ltd(600369) indicates that the effectiveness of basic immunization of existing vaccines for Omicron is low in terms of mutant strains. The enhanced immunization of vaccines of various technical routes against Omicron is slightly weaker than delta strain, but still can maintain a high level of neutralizing antibody. Covid-19 vaccine, neutralizing antibody and small molecule oral medicine are effective combinations for anti epidemic.
